A 6 week prospective randomized comparative study of metabolic adverse effects of Risperidone and Iloperidone in patients with schizophrenia

---

Original Article

Author Details : Anil Kumar Mysore Nagaraj, Priya Janardhan, Basavanna PL, Rajendra Rajagopal

Volume : 2, Issue : 3, Year : 2016

Article Page : 64-68

Suggest article by email

Get Permission

---

Abstract

Introduction: The antipsychotics Risperidone and Iloperidone are the two different benzisoxazole derivatives that are structurally different and metabolized differently. Risperidone has moderate effects on metabolic parameters. Iloperidone is comparable to placebo in this regard according to western literature. We wish to study this on Indian population.
Methods: it is a prospective randomized study having three visits, on day 1, 21 and 42. Forty patients with schizophrenia, 20 each on Risperidone and Iloperidone were compared for weight, BMI, FBS, PPBS and fasting lipid profile using repeated measures ANOVA and t test.
Results: Ten percent of subjects on Risperidone and 15% on Iloperidone had significant weight gain. The mean weight gain was 2.5 kg and 2.75 kg with Risperidone and Iloperidone respectively. Both weight and BMI were comparable. Within the group, Risperidone caused significant rise in lipids; where as Iloperidone caused significant increase in both lipids and sugar. Across the groups there was no significant difference.
Conclusions: The study reveals that Iloperidone is associated with weight gain, change in BMI as well as alteration in blood sugar and lipids that is comparable with Risperidone, even at a lower chlorpromazine equivalent dose, in contrast to the western literature where, its impact on metabolic parameters are said to be at placebo level.

Keywords: BMI, Cholesterol, FBS, Ilopridone, PPBS, Risperidone, Triglycerides, Weight gain

How to cite : Nagaraj A K M, Janardhan P, Basavanna Pl, Rajagopal R, A 6 week prospective randomized comparative study of metabolic adverse effects of Risperidone and Iloperidone in patients with schizophrenia. IP Indian J Neurosci 2016;2(3):64-68

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.